Coin flip: Top analyst gives Amylyx ALS drug a 50% chance at approval as rare second adcomm approaches

Max Gelman

Senior Editor

It’s late August. We’re in the dog days of summer. Seemingly everyone in biopharma has reported their first-half earnings and taken vacation, getting some R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Coin flip: Top analyst gives Amylyx ALS drug a 50% chance at approval as rare second adcomm approaches

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Coin flip: Top an­a­lyst gives Amy­lyx ALS drug a 50% chance at ap­proval as rare sec­ond ad­comm ap­proach­es

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Coin flip: Top analyst gives Amylyx ALS drug a 50% chance at approval as rare second adcomm approaches

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs